Abstract
Nigella sativa seeds are traditionally reputed as possessing anti-diabetic properties. As a result, we aim to explore the mechanism of its anti-hyperglycemic activity. The present study uses various experimental designs including gastrointestinal (GI) motility, intestinal disaccharidase activity and inhibition of carbohydrate digestion and absorption in the gut. The animals used as type 2 diabetic models were induced with streptozotocin to make them as such. Oral glucose tolerance test was performed to confirm that the animals were indeed diabetic. The extract reduced postprandial glucose, suggesting it interfered with glucose absorption in the gut. It also improved glucose (2.5g/kg, b/w) tolerance in rats. Furthermore, treatment with N. sativa produced a significant improvement in GI motility, while reduced disaccharidase enzyme activity in fasted rats. The extract produced a similar effect within an acute oral sucrose (2.5g/kg, b/w) load assay. Following sucrose administration, a substantial amount of unabsorbed sucrose was found in six different parts of the GI tract. This indicates that N. sativa has the potentiality to liberate GI content and reduce or delay glucose absorption. A potential hypoglycemic activity of the extract found in insulin release assay, where the extract significantly improved insulin secretion from isolated rat islets. These concluded present findings give rise to the implication that N. sativa seeds are generating postprandial anti-hyperglycemic activity within type 2 diabetic animal models via reducing or delaying carbohydrate digestion and absorption in the gut as well as improving insulin secretion in response to the plasma glucose.
Highlights
Diabetes Mellitus (DM) is a chronic and complex metabolic group of disorders—its prevalence has increased rapidly on a global scale
N. sativa powder illustrated the capacity of glucose adsorption at different concentrations of glucose within the solutions
This activity of adsorption continued from high concentrations of glucose to low concentrations of glucose (P
Summary
Diabetes Mellitus (DM) is a chronic and complex metabolic group of disorders—its prevalence has increased rapidly on a global scale. Mortality rates for DM are estimated to reach a total of 2.9 million deaths by the year 2030. Diabetes is cited as a significant global threat to public health [1,2], with 246 million individuals with this polygenic disorder around the world. Eighty percent reside in developing countries [3]. Diabetes is ranked seventh among the leading causes of mortality globally [4]. Type 2 DM is the most common and one of the life-threatening disease conditions among the current classified types. Type 2 DM is usually manifested via obesity and genetic disposition [5]. The presence of aldohexose in the circulation over an extended period combined with the License 4.0 (CC BY)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
